Yes, Stelara (ustekinumab) is classified as a specialty drug by insurers and pharmacy benefit managers. It checks every box that defines the specialty category: high cost, complex administration, cold-chain storage requirements, mandatory clinical monitoring, and distribution through specialty pharmacies rather than standard retail pharmacies.
What Makes Stelara a Specialty Drug
There’s no single official “specialty drug” stamp from the FDA. Instead, health insurers and pharmacy benefit managers use a set of criteria to classify medications as specialty, and Stelara meets nearly all of them. UnitedHealthcare, for example, lists Stelara and its biosimilars under its medical benefit specialty medication program. Most major insurers do the same.
The criteria that push Stelara into this category include its biologic nature (it’s a lab-engineered protein, not a simple chemical compound), its price point, and the level of clinical oversight it requires. Specialty drugs generally cost thousands of dollars per dose and need special handling or monitoring. Stelara qualifies on all counts.
How Stelara Is Administered
Stelara can be given two ways depending on the condition being treated, and neither is as simple as swallowing a pill. For plaque psoriasis and psoriatic arthritis, it’s injected under the skin. For Crohn’s disease and ulcerative colitis, the first dose is given as an intravenous infusion over at least one hour in a clinical setting, followed by subcutaneous injections every eight weeks for maintenance.
The IV infusion requires specialized equipment, including an infusion set with a specific in-line filter. The medication itself must be kept refrigerated and never frozen. Once diluted for infusion, it has a limited window before it must be used, typically three to four hours at room temperature for a standard bag. These handling requirements are a hallmark of specialty drugs and one reason they can’t simply sit on a retail pharmacy shelf.
Conditions Stelara Treats
Stelara is FDA-approved for four conditions in adults: moderate to severe plaque psoriasis, active psoriatic arthritis, moderately to severely active Crohn’s disease, and moderately to severely active ulcerative colitis. It’s also approved for children six and older with moderate to severe plaque psoriasis or active psoriatic arthritis. The drug works by blocking two immune signaling proteins (interleukin-12 and interleukin-23) that drive inflammation in these conditions.
This broad range of indications is typical of specialty biologics, which often treat chronic autoimmune and inflammatory diseases that haven’t responded well to simpler therapies.
Monitoring Requirements
Specialty drugs demand closer medical oversight than standard prescriptions, and Stelara is no exception. Before starting treatment, you’ll need to be tested for tuberculosis. If you have latent TB or a history of it, your doctor will want to treat that first, because Stelara suppresses parts of the immune system that keep TB in check.
Once you’re on Stelara, ongoing monitoring includes watching for signs of serious infections, skin cancer (particularly in patients over 60 or those with a history of prolonged immunosuppressant use), and a rare neurological condition called posterior reversible encephalopathy syndrome. If you take other medications that are processed by certain liver enzymes, your doctor may also need to adjust those doses when you start or stop Stelara, since it can shift how your body metabolizes other drugs.
This level of surveillance is part of what separates specialty drugs from medications you pick up at a corner pharmacy with minimal follow-up.
Where You Can Fill It
Stelara is dispensed through specialty pharmacies, not standard retail pharmacies. According to its manufacturer, Janssen Biotech, the drug is “widely available through open distribution at any specialty pharmacy of choice,” meaning you’re not locked into a single pharmacy network. Still, you won’t find it at a typical Walgreens or CVS retail counter.
Specialty pharmacies offer services that regular pharmacies don’t: temperature-controlled shipping, patient education, refill coordination, and sometimes nurse support for self-injection training. Many insurers require you to use a designated specialty pharmacy to get coverage, so it’s worth checking your plan’s requirements before your first fill.
Cost and Financial Assistance
The price is perhaps the most immediately felt aspect of Stelara’s specialty drug status. Its wholesale acquisition cost has risen nearly 199% since the drug launched in 2009, though the manufacturer treats the exact dollar figures as confidential. For context, specialty drugs in this class commonly run into thousands of dollars per injection, and Stelara is no exception.
Janssen offers financial support programs depending on your insurance situation. If you have commercial or private insurance, there’s a savings program that can reduce your out-of-pocket cost. Separate programs exist for patients on government insurance (like Medicare or Medicaid) and for those with no coverage at all. These programs are worth exploring, since specialty drug copays under insurance can still run into the hundreds or even thousands per dose depending on your plan’s tier structure.
Biosimilars May Lower Costs
The FDA has approved several biosimilars to Stelara, including Wezlana, which received interchangeable status. That designation means pharmacists can substitute it for Stelara without needing to contact your prescriber, similar to how generic drugs replace brand-name medications. Other biosimilars in the pipeline include Imuldosa, Otulfi, Steqeyma, and Yesintek, all of which UnitedHealthcare has already added to its specialty medication review process.
Biosimilars are expected to cost less than the brand-name version, though they’ll still be classified as specialty drugs. The same storage, monitoring, and administration requirements apply. The practical difference for patients is potentially lower copays and broader access, not a shift in how the drug is handled or prescribed.